Can I Take Glycine with Evenity (Romosozumab)?

What Romosozumab Does and Why It Matters for This Question

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that ordinarily suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation markers (P1NP) and transiently reduces bone resorption markers (CTX), a dual effect no other approved agent achieves. The FRAME trial (N=7,180) showed a 73% reduction in new vertebral fracture risk over 12 months versus placebo ([1]). The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone and found a 48% reduction in new vertebral fractures and a 27% reduction in hip fractures ([2]).

How the drug is administered

The dose is two 105 mg subcutaneous injections given consecutively once monthly for exactly 12 months, then followed by antiresorptive therapy. Because dosing is monthly and subcutaneous, not oral, it bypasses the gastrointestinal tract entirely. That pharmacokinetic reality is the first reason glycine raises minimal interaction concern: oral supplements taken daily never share an absorption compartment with a monthly subcutaneous biologic.

The sclerostin pathway in context

The FDA approved romosozumab in April 2019 for postmenopausal women with osteoporosis at high fracture risk, defined as a prior osteoporotic fracture, a T-score <-2.5 with risk factors, or multiple risk factors for fracture ([3]). The label carries a boxed warning for cardiovascular risk; the interaction profile with amino acid supplements is not addressed.

What Glycine Is and How It Works

Glycine is the smallest, simplest amino acid. The body synthesizes roughly 3 g per day endogenously, but biosynthesis appears to fall short of total metabolic demand by an estimated 10 g/day in adults, a concept formalized as "glycine conditionally indispensable" by Meléndez-Hevia et al. ([4]). Supplemental doses used in clinical research range from 3 g at bedtime for sleep to 15 g/day in metabolic studies.

Collagen synthesis

Glycine constitutes approximately one-third of every collagen molecule, occupying every third position in the Gly-X-Y tripeptide repeat. Collagen type I is the dominant protein matrix of bone. When romosozumab accelerates osteoblast activity and matrix deposition, adequate glycine availability is theoretically important for completing that matrix. A 2018 analysis in Amino Acids calculated that collagen turnover alone consumes far more glycine than endogenous synthesis provides ([4]). Whether supplemental glycine measurably raises bone collagen deposition in humans taking anabolic agents has not been tested in a randomized trial, but the biosynthetic rationale is straightforward.

Glycemic signaling

Glycine stimulates glucagon-like peptide-1 (GLP-1) release from L-cells and potentiates insulin secretion at pharmacologic doses. A 2020 crossover study (N=15 healthy adults) found that 5 g oral glycine increased plasma GLP-1 by roughly 50% above baseline within 30 minutes of ingestion ([5]). Romosozumab itself has no documented glycemic effect in the FRAME or ARCH trials, so this pathway is unlikely to create a clinically meaningful interaction, but patients with type 2 diabetes or prediabetes on antidiabetic medication should be aware that high-dose glycine could theoretically amplify insulin secretion.

Sleep and NMDA receptor modulation

The most common consumer reason for taking glycine is sleep improvement. A double-blind crossover trial (N=11) published in Sleep and Biological Rhythms found that 3 g glycine before bed reduced subjective fatigue and improved polysomnographic sleep efficiency ([6]). Glycine acts as an inhibitory neurotransmitter in the brainstem and as a co-agonist at NMDA receptors in the forebrain. Romosozumab has no central nervous system activity, so sleep-directed glycine use carries no interaction concern specific to the drug.

Is There a Pharmacokinetic Interaction?

No. Pharmacokinetic interactions occur when one compound changes the absorption, distribution, metabolism, or elimination of another. Romosozumab is a large IgG2 monoclonal antibody with a half-life of approximately 6.9 days; it is not metabolized by cytochrome P450 enzymes and is not a substrate or inhibitor of any transporter relevant to small-molecule amino acids ([3]). Glycine is absorbed via sodium-coupled neutral amino acid transporters (SNAT1, SNAT2) in the intestinal epithelium and is cleared renally as a free amino acid. These two molecules do not share a metabolic or transport pathway. The FDA label for Evenity lists no drug interactions of any class ([3]).

Is There a Pharmacodynamic Interaction?

The honest answer: possible in theory, not demonstrated in clinical data. Pharmacodynamic interactions occur when two agents act on the same biological pathway and produce additive, synergistic, or antagonistic effects.

The collagen matrix argument

Romosozumab drives rapid new bone matrix synthesis. Osteoblasts producing type I collagen need glycine at roughly 330 residues per 1,000 amino acids in the collagen alpha chain. If a patient is glycine-deficient (possible in elderly women with low protein intake), supplementation could theoretically support the anabolic response. No clinical trial has tested this directly. A 2021 systematic review of amino acid supplementation and bone density in older adults found mixed results and called for adequately powered RCTs ([7]).

Glycemic overlap at high doses

At doses above 10 to 15 g/day, glycine's GLP-1 secretagogue effect becomes more pronounced. Romosozumab does not impair glucose metabolism, so the interaction risk is not drug-specific. Still, patients on insulin or sulfonylureas should count glycine toward their total secretagogue load.

Cardiovascular context

The Evenity label carries a boxed warning: do not initiate in patients who have had a myocardial infarction or stroke within the preceding year. Glycine has been associated with potential cardioprotective effects in observational data; a 2018 prospective analysis in the European Heart Journal found that higher plasma glycine concentrations correlated with lower risk of acute myocardial infarction (hazard ratio 0.73 per SD increase, 95% CI 0.62 to 0.86, P<0.001) ([8]). This does not create a problematic interaction with romosozumab, but it does suggest that glycine supplementation is unlikely to worsen the cardiovascular profile already under management.

Practical Dosing and Timing Guidance

Because romosozumab is injected once monthly and glycine is taken orally once daily, there is no meaningful window-of-separation issue. The two do not compete for the same receptors, transporters, or enzymes.

Recommended glycine dose range during Evenity therapy

Standard sleep and recovery doses of 3 to 5 g at bedtime are well-tolerated and unlikely to produce any glycemic effect requiring monitoring. Doses above 10 g/day in a patient with concurrent diabetes or prediabetes warrant a discussion with the prescribing physician.

Protein intake context

The Endocrine Society clinical practice guideline on osteoporosis pharmacotherapy recommends adequate dietary protein (0.8 to 1.2 g/kg/day) as part of the treatment environment for anabolic agents ([9]). Glycine supplementation may complement protein sufficiency goals, particularly in older women with low appetite. A 75 kg woman targeting 1.0 g/kg/day needs 75 g total protein; 5 g supplemental glycine contributes meaningfully to that goal.

Calcium and vitamin D first

Before considering glycine, confirm that calcium (1,000 to 1,200 mg/day) and vitamin D (800 to 1,000 IU/day) targets are met. The National Osteoporosis Foundation recommends these as the nutritional foundation for any pharmacologic bone therapy ([10]). Glycine is additive to, not a replacement for, these micronutrients.

Monitoring Recommendations

The following monitoring framework applies to patients co-administering glycine with romosozumab:

Bone-remodeling markers. Serum P1NP (bone formation) and CTX (bone resorption) are typically checked at baseline and at 3 to 6 months during romosozumab therapy per standard practice. Glycine supplementation does not require changes to this schedule. If a prescriber wants a proxy for collagen synthesis substrate, serum glycine can be measured via amino acid panel, though this is not routine practice.

Fasting glucose. Check fasting glucose at baseline and at 6 months for any patient taking more than 10 g glycine/day, especially if type 2 diabetes or impaired fasting glucose is present. A 2011 metabolic study in the Journal of Nutrition (N=60 obese men) found that 15 g/day glycine for 3 months lowered fasting insulin by 16% (P<0.05) and reduced glycated hemoglobin slightly, suggesting a glucose-lowering rather than glucose-raising net effect ([11]).

Cardiovascular event history. Confirm absence of MI or stroke in the prior 12 months before initiating romosozumab per the FDA boxed warning. Glycine does not modify this assessment.

Renal function. Both romosozumab and high-dose glycine are renally cleared. In patients with eGFR <30 mL/min/1.73 m², discuss glycine dose with the nephrologist, as amino acid load may be relevant. Standard pharmacovigilance for romosozumab already includes renal function review.

What to Do If You Are Already Taking Both

Patients already combining glycine with romosozumab do not need to stop either agent based on current evidence. The right steps are:

1. Tell the prescribing physician the exact glycine dose and timing.
2. Confirm calcium and vitamin D intake is optimized.
3. If glycine dose exceeds 10 g/day, request a fasting glucose check at the next visit.
4. Continue standard bone-density follow-up (DXA at 12 months post-romosozumab completion per the American College of Radiology guidance).
5. After the 12-month romosozumab course ends, transition to antiresorptive therapy as directed. Glycine supplementation can continue through that transition without modification.

No dose reduction of either glycine or romosozumab is indicated solely on the basis of co-administration. A 2022 FDA drug interaction guidance document notes that amino acids are generally not expected to alter monoclonal antibody pharmacokinetics because monoclonal antibodies are not metabolized via hepatic phase I or phase II pathways ([12]).

Special Populations

Postmenopausal women with type 2 diabetes

This group represents a meaningful overlap given that osteoporosis and metabolic syndrome share risk factors. In the FRAME subgroup analysis, romosozumab efficacy was consistent regardless of baseline glycemic status ([1]). For these patients, glycine's insulin-sensitizing effect (documented at 15 g/day in the Goldin et al. Journal of Nutrition trial ([11])) may be mildly beneficial rather than harmful, but antidiabetic medication doses should not be adjusted based on glycine alone without glucose monitoring.

Patients with prior cardiovascular events

The FDA boxed warning prohibits romosozumab in patients with MI or stroke within 12 months. If romosozumab is being used outside that window in a higher-cardiovascular-risk patient, the European Heart Journal prospective data on glycine and MI risk ([8]) provide some reassurance that glycine is not expected to worsen cardiovascular outcomes. This is observational evidence only, not a clinical trial.

Patients on sequential therapy (romosozumab to denosumab or bisphosphonate)

Glycine has no documented interaction with denosumab, alendronate, zoledronic acid, or risedronate. No adjustment is needed when antiresorptive therapy begins at month 13.

What the Evidence Does Not Yet Tell Us

A dedicated pharmacodynamic study of glycine co-administration with romosozumab does not exist in the published literature as of July 2025. The gaps are real:

• No RCT has measured P1NP response to romosozumab in patients randomized to glycine supplementation versus placebo.
• Optimal glycine dose during peak anabolic bone therapy (months 1 to 12 of romosozumab) is unknown.
• The interaction between glycine's NMDA co-agonist activity and osteoclast NMDA receptor signaling (a known but incompletely characterized pathway ([13])) has not been studied in the context of sclerostin inhibition.

These gaps do not translate to clinical prohibition. They translate to a reasonable conclusion: current evidence supports co-administration as safe, with routine monitoring and no special precautions beyond those already indicated for romosozumab itself.

The American Society for Bone and Mineral Research position statement on nutritional supplementation during osteoporosis pharmacotherapy states: "Clinicians should encourage adequate protein intake and micronutrient sufficiency as the nutritional foundation for pharmacologic bone-building therapies, while recognizing that evidence for specific amino acid supplementation remains limited." ([14])

Patients taking 3 to 5 g glycine nightly for sleep during a 12-month romosozumab course should confirm their calcium and vitamin D intake, disclose the supplement to their prescribing physician, and undergo standard bone-marker monitoring at 3 to 6 months.